Adam Feuerstein
Even after Vidaza picked up its survival claim, the market share between the two drugs didn't move all that much, with both still getting somewhere close to 50% of patients. (Vidaza a bit more today.)
My point is that unless the EORTC study results are spectacular in either direction, U.S. market share is likely to stay fairly constant. A Dacogen survival benefit will help SuperGen's European partner, Johnson & Johnson (JNJ Quote - Cramer on JNJ - Stock Picks), seek approval, so that's a good thing. So, Dacogen will continue to provide steady royalty income for SuperGen (good); there is about $90 million in the bank (good); and the company's pipeline consists of some interesting albeit early-stage cancer drugs (good, if they pan out, but at this point, who knows?). Overall, SuperGen is not a bad story at all, and if this Dacogen study comes out positive, the stock will likely move higher.Next up is Paul S., who asks, "What is your current opinion on Myriad Genetics (MYGN Quote - Cramer on MYGN - Stock Picks)? Its phase III Alzheimer's trial of Flurizan should have ended March 31, and the ongoing phase II trials of its brain cancer therapy should be completed later this year. The stock seems stuck dead in the water, and the company has been silent recently." Paul is correct, the results from the phase III Flurizan study in mild Alzheimer's patients are expected soon, likely the June-July time frame. The company has already said that the data will be presented at the International Conference on Alzheimer's Disease, which kicks off July 26 in Chicago.
RSS
